{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:07:18Z","timestamp":1784786838593,"version":"3.55.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epcoritamab shows potentially curable efficacy in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma, but potential heterogeneity in its adverse events (AEs) across demographics and dosing regimens remain unexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study comprehensively analyzed potential heterogeneity of epcoritamab associated AEs using the data from the FDA Adverse Event Reporting System (FAERS) database and supplemented it with data from the Japanese Adverse Drug Event Report (JADER) database. Based on the clinical characteristics of the epcoritamab-associated AE reports, the potential heterogeneity of AEs across demographic and dosing regimen subgroups was investigated via reporting odds ratio algorithm and Fisher\u2019s exact test with Bonferroni correction. Subsequently, sensitivity analysis was performed to validate the potential variations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients receiving 0.16\u202fmg dose reported significantly higher frequency of cytokine release syndrome (CRS), especially within the first four treatment weeks. Immune effector cell-associated neurotoxicity syndrome (ICANS) was reported with a significantly higher frequency among patients over the age of 65 compared to those aged 18\u201365.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study revealed the potential heterogeneity of epcoritamab associated AEs in demographics and dosing regimens. Enhanced CRS monitoring should be prioritized during the initial administration of epcoritamab treatment. Monitoring ICANS may be of particular importance in older patients. Further research is warranted to elucidate the case causality of these associations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1832550","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:41:18Z","timestamp":1784785278000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential heterogeneity of epcoritamab associated adverse events in demographics and dosing regimens"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhongming","family":"Yu","sequence":"first","affiliation":[{"name":"Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province","place":["Hangzhou, Zhejiang, China"]},{"name":"Zhejiang Provincial Key Laboratory of Disease-Syndrome Integrated Cancer Prevention and Treatment, Tongde Hospital of Zhejiang Province","place":["Hangzhou, Zhejiang, China"]},{"name":"Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Pharmacodynamic Material Basis Research of Chinese Medicine, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrui","family":"Jin","sequence":"additional","affiliation":[{"name":"Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilu","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-Hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","article-title":"B-cell non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12254-017-0367-8","article-title":"Aggressive lymphoma 2016: revision of the WHO classification","volume":"10","author":"Beham-Schmid","year":"2017","journal-title":"Memo"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"100325","DOI":"10.1016\/j.lrr.2022.100325","article-title":"Immunotherapy in indolent non-Hodgkin's lymphoma","volume":"17","author":"Amhaz","year":"2022","journal-title":"Leuk Res Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and etiology of diffuse large B-cell lymphoma","volume":"60","author":"Wang","year":"2023","journal-title":"Semin Hematol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40364-024-00605-w","article-title":"Single-cell and spatial transcriptomics reveal a high glycolysis B cell and tumor-associated macrophages cluster correlated with poor prognosis and exhausted immune microenvironment in diffuse large B-cell lymphoma","volume":"12","author":"Dai","year":"2024","journal-title":"Biomark Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"8553","DOI":"10.3390\/ijms21228553","article-title":"Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"21","author":"Harris","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/blood-2018-08-822148","article-title":"How I treat early-relapsing follicular lymphoma","volume":"133","author":"Casulo","year":"2019","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"ref11","first-page":"790","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume-title":"Am J Hematol","author":"Al-Hamadani","year":"2015"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e008338","DOI":"10.1136\/jitc-2023-008338","article-title":"Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20xCD3 bispecific antibody, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"12","author":"Brouwer-Visser","year":"2024","journal-title":"J Immunother Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1182\/bloodadvances.2022008802","article-title":"Ibrutinib plus RICE or RVICI for relapsed\/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial","volume":"7","author":"Burke","year":"2023","journal-title":"Blood Adv"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11864-021-00925-1","article-title":"Bispecific antibodies for non-Hodgkin lymphoma treatment","volume":"23","author":"Bock","year":"2022","journal-title":"Curr Treat Options in Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2297450","DOI":"10.1080\/19420862.2023.2297450","article-title":"Antibodies to watch in 2024","volume":"16","author":"Crescioli","year":"2024","journal-title":"MAbs"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3xCD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting","volume":"7","author":"Mhibik","year":"2023","journal-title":"Blood Adv"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40265-023-01930-4","article-title":"Epcoritamab: first approval","volume":"83","author":"Frampton","year":"2023","journal-title":"Drugs"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2024.2310148","article-title":"Epcoritamab in B-cell malignancies: current status and prospects","volume":"24","author":"Molica","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/14740338.2025.2470875","article-title":"Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database","volume":"24","author":"Le","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with Secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Shu","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/0113894501290296240327081624","article-title":"Drug repurposing using FDA adverse event reporting system (FAERS) database","volume":"25","author":"Morris","year":"2024","journal-title":"Curr Drug Targets"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/7882277","article-title":"Analysis of adverse reactions of aspirin in prophylaxis medication based on FAERS database","volume":"2022","author":"Ren","year":"2022","journal-title":"Comput Math Methods Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e1161","DOI":"10.1002\/prp2.1161","article-title":"Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety","volume":"12","author":"Jiang","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"11388","DOI":"10.1038\/s41598-024-62356-w","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib","volume":"14","author":"Qi","year":"2024","journal-title":"Sci Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/14740338.2024.2371382","article-title":"Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database","volume":"24","author":"Wan","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s10194-024-01858-4","article-title":"Post-marketing safety concerns with rimegepant based on a pharmacovigilance study","volume":"25","author":"Hu","year":"2024","journal-title":"J Headache Pain"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"20420986241258049","DOI":"10.1177\/20420986241258049","article-title":"A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime","volume":"15","author":"Jiang","year":"2024","journal-title":"Ther Adv Drug Saf"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"20420986231154075","DOI":"10.1177\/20420986231154075","article-title":"Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database","volume":"14","author":"Altebainawi","year":"2023","journal-title":"Ther Adv Drug Saf"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000505376","article-title":"Fractures due to aromatase inhibitor therapy for breast Cancer: a real-world analysis of FAERS data in the past 15 years","volume":"43","author":"Song","year":"2020","journal-title":"Oncol Res Treat"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","volume":"12","author":"Guo","year":"2022","journal-title":"Sci Rep"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.18433\/jpps33020","article-title":"Post-marketing safety of Vemurafenib: a real-world pharmacovigilance study of the FDA adverse event reporting system","volume":"25","author":"Liu","year":"2022","journal-title":"J Pharm Pharm Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1251961","DOI":"10.3389\/fphar.2024.1251961","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor","volume":"15","author":"Pan","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pds.4944","article-title":"Quality evaluation of the Japanese adverse drug event report database (JADER)","volume":"29","author":"Tsuchiya","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"ref40","year":"2023"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell-engaging bispecific antibodies: current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2217\/imt-2019-0074","article-title":"Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies","volume":"11","author":"Khadka","year":"2019","journal-title":"Immunotherapy"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e70236","DOI":"10.1111\/ene.70236","article-title":"Baseline cognitive and neurological status does not modify the occurrence of ICANS in CAR T-cell therapy for aggressive B-cell lymphoma","volume":"32","author":"Ursu","year":"2025","journal-title":"Eur J Neurol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.17.25320737","article-title":"Novel risk factors for predicting immune effector cell-associated neurotoxicity syndrome","author":"Friedman","year":"2025","journal-title":"medRxiv"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.20471\/acc.2022.61.s1.11","article-title":"Sepsis definition: what's new in the treatment guidelines","volume":"61","author":"Srzic","year":"2022","journal-title":"Acta Clin Croat"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jclinepi.2023.08.010","article-title":"Pharmacovigilance studies without a priori hypothesis: systematic review highlights inappropriate multiple testing correction procedures","volume":"162","author":"Gaucher","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.chmed.2025.11.005","article-title":"A review of Siraitia grosvenorii: applications, breeding, and biosynthesis of mogrosides","volume":"18","author":"Luo","year":"2025","journal-title":"Chin Herb Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.chmed.2025.11.004","article-title":"Advances in microbial biosynthesis of indirubin","volume":"18","author":"Li","year":"2025","journal-title":"Chin Herb Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.chmed.2024.04.004","article-title":"Paris saponin VII induces Caspase-3\/GSDME-dependent pyroptosis in pancreatic ductal adenocarcinoma cells by activating ROS\/Bax signaling","volume":"17","author":"Qian","year":"2025","journal-title":"Chin Herb Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.chmed.2025.04.006","article-title":"Curcumae Rhizoma: An anti-cancer traditional Chinese medicine","volume":"17","author":"Luo","year":"2025","journal-title":"Chin Herb Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.chmed.2025.04.002","article-title":"Mechanisms and benefits of phytochemicals as an alternative therapeutic strategy in female cancers","volume":"17","author":"Zhao","year":"2025","journal-title":"Chin Herb Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.chmed.2023.07.002","article-title":"Ethnopharmacology, chemical composition and functions of Cymbopogon citratus","volume":"16","author":"Du","year":"2024","journal-title":"Chin Herb Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1832550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:41:19Z","timestamp":1784785279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1832550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":59,"alternative-id":["10.3389\/fmed.2026.1832550"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1832550","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"article-number":"1832550"}}